Hematopoietic stem cell-derived myeloid and plasmacytoid DC-based vaccines are highly potent inducers of tumor-reactive T cell and NK cell responses ex vivo

Author(s):
Thordardottir, S.; Schaap, N.; Louer, E.; Kester, M.G.D.; Falkenburg, J.H.F. (0000-0002-9819-4813); Jansen, J.; Radstake, T.R.D.; Hobo, W.; Dolstra, H.
Published
2017
Publication type
Article / Letter to editor
Antitumor immunitydendritic cellsgraft-versus-tumor immunityhematopoietic stem and progenitor cellmDCNK cellpDCT cellvaccination
Date issued
2017-12-31
Language
English
Is part of
OncoImmunology (2017), No. 3
hdl
1887/115897
doi
10.1080/2162402X.2017.1285991